Table 2

Characteristics of the participants in the 119 randomised controlled trials included in our analysis (n=18 919, ranging from 30 to 3789 patients per trial)

CharacteristicNo. of patients (%)
Weighted mean age ± weighted SD43.5±12.0 years
Female13 697 (72.4)
Eligibility criteria
 ACR RA alone8994 (47.5)
 ACR RA+1 TCM syndrome*3040 (16.1)
 ACR RA+2 TCM syndromes*332 (1.8)
 ACR RA+≥3 TCM syndromes*1072 (5.7)
 ACR RA+unspecified number TCM syndromes*300 (1.6)
 ACR RA+TCM syndrome (not guideline driven)5181 (27.4)
Median disease duration (range)5.4 years (0.04–28 years)
Interventions
 CHM alone10 108 (53.4)
 CHM+DMARDs1595 (8.4)
 CHM+DMARDs+NSAIDs511 (2.7)
 CHM+DMARDs+steroids+NSAIDs79 (0.4)
 CHM+steroids501 (2.6)
 CHM+steroids+NSAIDs200 (1.1)
 CHM+NSAIDs2101 (11.1)
 CHM+NSAIDs+antibiotic74 (0.4)
 DMARDs alone1402 (7.4)
 DMARDs+steroids78 (0.4)
 DMARDs+steroids+NSAIDs363 (1.9)
 DMARDs+NSAIDs992 (5.2)
 NSAIDs+antibiotic56 (0.3)
 NSAIDs alone644 (3.4)
 Antibiotic†50 (0.3)
 Placebo alone165 (0.9)
Previous WM treatment‡8518 (45.0)
Most common patterns reported§
 Dampness-heat blockage1023 (10.3)
 Dampness-cold and qi deficiency-blood stasis557 (5.6)
 Heat-cold complex512 (5.2)
 Dampness-cold blockage300 (3.0)
 Dampness-heat and qi deficiency-blood stasis269 (2.7)
Qi deficiency and blood stasis226 (2.3)
Yin deficiency178 (1.8)
  • *Chinese medical syndrome following governmental guidelines.

  • †Penicillin.

  • ‡Only 49 studies reported data.

  • §Percentages are based on the 46 studies in which eligibility criteria included diagnosis with at least 1 TCM syndrome (n=9925).

  • ACR RA, American College of Rheumatology classification criteria for rheumatoid arthritis; CHM, Chinese herbal medicine; DMARDs, disease-modifying antirheumatic drugs; NSAIDs, non-steroidal anti-inflammatory drugs; TCM syndrome, traditional Chinese medicine syndrome; WM, western medicine.